Table 1.
Patient demographics and baselinea disease characteristics
| Characteristic | Dose-up (N = 280) | Stay-on 5 (N = 757) | Dose-down (N = 476) | Stay-on 10 (N = 2440) |
|---|---|---|---|---|
| Age (years), mean (range) | 51.7 (20.0–75.0) | 53.6 (18.0–81.0) | 55.5 (20.0–86.0) | 53.0 (18.0–85.0) |
| Female, n (%) | 231 (82.5) | 630 (83.2) | 395 (83.0) | 1980 (81.1) |
| Race, n (%) | ||||
| White | 191 (68.2) | 489 (64.6) | 325 (68.3) | 1842 (75.5) |
| Black | 7 (2.5) | 18 (2.4) | 17 (3.6) | 76 (3.1) |
| Asian | 53 (18.9) | 157 (20.7) | 90 (18.9) | 266 (10.9) |
| Other | 29 (10.4) | 93 (12.3) | 44 (9.2) | 256 (10.5) |
| RA duration (years), mean (range) | 8.0 (0.7–49.5) | 9.7 (0.7–46.5) | 9.7 (0.6–50.6) | 8.7 (0.3–55.5) |
| DAS28, mean (SD) | 4.5 (1.6) | 3.7 (1.3) | 3.4 (1.2) | 3.6 (1.3) |
| HAQ-DI, mean (SD) | 1.0 (0.7) | 0.8 (0.7) | 0.7 (0.7) | 0.8 (0.7) |
| CDAI, mean (SD) | 18.1 (14.0) | 11.4 (9.8) | 8.5 (8.6) | 10.3 (9.9) |
| SDAI, mean (SD) | 18.9 (14.4) | 11.8 (9.8) | 9.0 (8.8) | 10.8 (10.0) |
| RF + , n (%) | 200 (71.4) | 538 (71.1) | 333 (70.0) | 1636 (67.0) |
| aCCP + , n (%)b | 101 (36.1) | 161 (21.3) | 334 (70.2) | 1701 (69.7) |
| Tofacitinib as monotherapy, n (%) | 107 (38.2) | 216 (28.5) | 163 (34.2) | 802 (32.9) |
| Corticosteroid use, n (%) | 148 (52.9) | 387 (51.1) | 218 (45.8) | 1231 (50.5) |
aAll values are for LTE baseline, except DAS28, HAQ-DI, CDAI, and SDAI, which are values at analysis baseline. For Dose-switch groups, analysis baseline was defined as the last observation before or on the day of the first dose switch. For Stay-on groups, analysis baseline was defined as month 3 LTE visit
bData were only available for 133 (48%) patients in the Dose-up group, 189 (25%) patients in the Stay-on 5 group, 447 (94%) patients in the Dose-down group, and 2236 (92%) patients in the Stay-on 10 group
aCCP + anti-cyclic citrullinated peptide positive, CDAI Clinical Disease Activity Index, DAS28 4-component disease activity score in 28 joints, erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, LTE long-term extension, N number of patients in treatment group, n number of patients with characteristic, RA rheumatoid arthritis, RF + rheumatoid factor positive; SD standard deviation, SDAI Simplified Disease Activity Index